Cost-effectiveness analyses of human papillomavirus vaccination
- 1 April 2007
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 7 (4), 289-296
- https://doi.org/10.1016/s1473-3099(07)70083-x
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and DiseaseEpidemiologic Reviews, 2006
- Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling AnalysesPLoS Medicine, 2006
- Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UKCurrent Medical Research and Opinion, 2006
- Need for differential discounting of costs and health effects in cost effectiveness analysesBMJ, 2005
- Role of Herd Immunity in Determining the Effect of Vaccines against Sexually Transmitted DiseaseThe Journal of Infectious Diseases, 2005
- Vaccination against human papillomavirus infection: a new paradigm in cervical cancer controlVaccine, 2005
- A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccineInternational Journal of Cancer, 2003
- The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus VaccineEpidemiology, 2002
- Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries,Published by Ovid Technologies (Wolters Kluwer Health) ,2002
- Comparison of Human Papillomavirus Types 16, 18, and 6 Capsid Antibody Responses Following Incident InfectionThe Journal of Infectious Diseases, 2000